Scandinavian Real Heart AB (HEART) AI Stock Analysis

• Market Cap: kr69.48M
• Dividend Yield: N/A
• Average Volume (3M): 8.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -4.60
• Shares Outstanding: 4,998,704
• 10 Day Avg. Volume: 7,608
• 30 Day Avg. Volume: 8,341
• PEG Ratio: 0.04
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Scandinavian Real Heart AB is facing significant financial and operational challenges, reflected in its low financial performance score due to ongoing losses and cash flow issues. The technical analysis presents mixed signals with no clear trend. Valuation metrics are unfavorable, with a negative P/E ratio indicating financial distress. These factors combine to create a cautious outlook for the stock, requiring significant operational improvements and strategic adjustments to enhance performance and investor confidence.

Scandinavian Real Heart AB Business Overview & Revenue Model

Company Description

Scandinavian Real Heart AB (HEART) is a Swedish medical technology company focused on developing advanced cardiac assist devices. The company specializes in creating innovative artificial heart solutions designed to improve the quality of life for patients with severe heart diseases. Their flagship product, the Total Artificial Heart, aims to replicate the functionality of a natural heart, providing a life-saving option for patients awaiting heart transplants.

How the Company Makes Money

Scandinavian Real Heart AB primarily generates revenue through the development and commercialization of its Total Artificial Heart technology. This involves securing partnerships with healthcare institutions and medical device distributors who facilitate the adoption and implementation of their products in clinical settings. Additionally, the company may receive funding through grants, research collaborations, and strategic alliances with larger medical technology firms. As the product progresses through clinical trials and regulatory approvals, sales and licensing agreements are expected to become significant revenue streams.

Scandinavian Real Heart AB Financial Statement Overview

Summary

Scandinavian Real Heart AB faces significant financial challenges, particularly in generating revenue and achieving profitability. The balance sheet shows relative stability, although increasing leverage is a concern. Persistent negative cash flows underscore the need for improved cash management or additional financing. Overall, the financial outlook requires careful monitoring and strategic adjustments to address these issues.

Income Statement

Scandinavian Real Heart AB has struggled to generate revenue, with total revenue consistently at or near zero in recent years. The company also reports persistent negative net income and EBIT margins, highlighting ongoing challenges in achieving profitability. The lack of revenue growth and negative profit margins suggest significant operational difficulties.

Balance Sheet

The company's balance sheet shows a high equity ratio, indicating a solid financial base with stockholders' equity making up the majority of total assets. However, the debt-to-equity ratio has been increasing, suggesting rising leverage. Despite this, the overall financial stability appears reasonable, though the lack of revenue raises concerns about future financial health.

Cash Flow

Cash flow analysis reveals ongoing negative free cash flow, driven by substantial capital expenditures and negative operating cash flow. The company's reliance on external financing is evident, raising concerns about sustainability. Operating cash flow is negative compared to net income, which may indicate cash flow management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	10.00K	0.00	0.00
	Gross Profit
-19.18M	-50.22M	12.29M	7.20M	332.76K
	EBIT
-34.15M	-68.45M	-13.85M	-10.33M	-8.64M
	EBITDA
-14.52M	-67.25M	-13.73M	-10.09M	-8.37M
	Net Income Common Stockholders
-34.35M	-67.98M	-13.99M	-10.48M	-8.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.72M	43.30M	11.26M	42.67M	22.45M
	Total Assets
83.28M	102.64M	119.82M	117.82M	78.04M
	Total Debt
6.35M	8.25M	2.17M	2.80M	3.42M
	Net Debt
-17.36M	-35.05M	-9.09M	-39.88M	-19.04M
	Total Liabilities
15.94M	20.60M	22.17M	6.53M	6.35M
	Stockholders Equity
67.34M	82.04M	97.65M	111.29M	71.69M
Cash Flow		Free Cash Flow
-38.25M	-26.82M	-31.14M	-29.24M	-24.18M
	Operating Cash Flow
-12.99M	-25.05M	-7.38M	-9.65M	-9.41M
	Investing Cash Flow
-24.28M	-1.77M	-23.76M	-19.59M	-14.76M
	Financing Cash Flow
17.69M	58.87M	-276.28K	49.46M	21.21M

Scandinavian Real Heart AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HEART, the sentiment is Negative. The current price of 13.9 is below the 20-day moving average (MA) of 14.52, below the 50-day MA of 14.61, and below the 200-day MA of 16.91, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 44.22 is Neutral, neither overbought nor oversold. The STOCH value of 38.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HEART.

Scandinavian Real Heart AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	€1.15B	35.49	10.11%	―	2.53%	-44.90%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
QLINEA	50 Neutral	€311.20M	―	-159.24%	―	-22.50%	76.74%
ACARIX	46 Neutral	€255.30M	―	-88.97%	―	-0.61%	54.19%
BACTI.B	46 Neutral	€1.05B	―	-7.30%	―	23.51%	80.47%
LXB	37 Underperform	€97.29M	―	-51.52%	―	955.20%	47.31%
HEART	34 Underperform	kr69.48M	―		―	―	―